Who are Optimized bismuth quadruple therapy's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/optimized-bismuth-quadruple-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Optimized bismuth quadruple therapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Optimized bismuth quadruple therapy (Optimized bismuth quadruple therapy) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic combination therapy / Bismuth-based H. pylori eradication regimen. Area: Gastroenterology / Infectious Disease.

marketed Antibiotic combination therapy / Bismuth-based H. pylori eradication regimen Gastroenterology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Optimized bismuth quadruple therapy (Optimized bismuth quadruple therapy) — Pontificia Universidad Catolica de Chile. Bismuth quadruple therapy combines bismuth subsalicylate with three antimicrobial agents to eradicate Helicobacter pylori infection through multiple mechanisms of action.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Optimized bismuth quadruple therapy TARGET	Optimized bismuth quadruple therapy	Pontificia Universidad Catolica de Chile	marketed	Antibiotic combination therapy / Bismuth-based H. pylori eradication regimen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic combination therapy / Bismuth-based H. pylori eradication regimen class)

Pontificia Universidad Catolica de Chile · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Optimized bismuth quadruple therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/optimized-bismuth-quadruple-therapy. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing